In 2025, significant advancements in cardiovascular managed care were spotlighted, showcasing a diverse range of developments from research breakthroughs to drug approvals and innovative patient monitoring strategies. Among the noteworthy findings, two pivotal studies published in The American Journal of Managed Care® (AJMC®) underscored the substantial benefits of remote patient monitoring for hypertension management and highlighted the variability in outcomes from different types of ambulatory cardiac monitors (ACMs). Additionally, expert interviews illuminated pressing cardiovascular health disparities in rural Louisiana, alongside crucial findings on atrial fibrillation. A major regulatory win came when the FDA expanded the labeling for semaglutide, a notable glucagon-like peptide-1 (GLP-1) receptor agonist.
One of the standout studies examined the impact of remote patient monitoring on stage 2 hypertension, involving 1,594 Medicare beneficiaries. This quasi-experimental study revealed a pronounced drop in mean systolic and diastolic pressure from 152/85 mm Hg to 132/74 mm Hg over a 12-month period. Notably, the percentage of patients still meeting stage 2 criteria plummeted from 100% to just 25%. Even among those typically resistant to treatment, significant blood pressure reductions were noted. These results bolster the argument that remote monitoring, coupled with structured nursing support, can significantly enhance adherence to treatment and facilitate timely medication adjustments for older adults battling uncontrolled hypertension.
In a groundbreaking trial known as AZALEA-TIMI 71, researchers found that abelacimab demonstrated a 62% reduction in major or clinically relevant non-major bleeding compared to rivaroxaban, particularly making strides in reducing gastrointestinal bleeding, which is a common cause for hospitalizations among atrial fibrillation patients. During an insightful discussion with AJMC, Dr. Christian Ruff and Dr. Dan Bloomfield emphasized the treatment’s potential benefits for older patients with multiple health issues, although they noted that extensive trials are still required to validate the drug’s efficacy in stroke prevention prior to moving toward approval.
Moreover, the importance of geographic and systemic challenges on cardiovascular health was underscored by Dr. Antoine Keller, founder of HeartSense. He indicated that geographic barriers, alongside clinician shortages and policy deficiencies, are exacerbating cardiovascular health disparities in rural Louisiana and the South. Issues such as food insecurity and inconsistent insurance coverage contribute to more severe disease manifestations, particularly in cases requiring advanced heart failure therapies. Dr. Keller urged that fostering better cardiovascular health in underserved areas will necessitate collective community efforts and significant policy reforms.
A retrospective cohort study involving over 428,000 commercially insured patients unveiled considerable variations in clinical and economic outcomes linked to different types of ACMs. Findings indicated that long-term continuous monitors not only correlated with higher rates of arrhythmia diagnoses but also resulted in fewer retests, lower risks of cardiovascular events, and decreased health care utilization compared to traditional Holters and external event monitors. This suggests that the manufacturer choice for ACMs is pivotal in determining diagnostic yield and cost-effectiveness.
In a major update for diabetes and chronic kidney disease patients, the FDA expanded the use of semaglutide in January 2025. Derived from results of the phase 3 FLOW trial, this approval links once-weekly semaglutide injections with reduced risks of cardiovascular disease and adverse kidney outcomes. As the first GLP-1 receptor agonist indicated for both cardiovascular disease risk mitigation and advanced kidney disease treatment, this development is poised to make a substantial impact on patient care.
These articles collectively underscore a year of promising progress in cardiovascular care, emphasizing the need for ongoing research and innovation to improve patient outcomes across diverse populations.
Original Source: https://www.ajmc.com/view/top-5-most-read-cardiovascular-content-of-2025
Category :
Tags:
Publish Date: 2025-12-31 03:08:00
